Mgi Pharma — BioCentury NewsMakers (September 2005)
16 slides from Mgi Pharma's conference presentation, Sep 9, 2005
Slide 1: Building a Leading Oncology and Acute Care Focused Biopharmaceutical Company
Building a Leading Oncology and Acute Care Focused Biopharmaceutical Company BioCentury NewsMakers September 9, 2005
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties, including those described in the Company’s Securities and Exchange Commission filings.
Slide 3: Building A Leading Biopharmaceutical Company
MGI PHARMA Building A Leading Biopharmaceutical Company Revenue potential >$1B within 5 years Aloxi® injection 1H05 sales of $118 M #1 share position in IV 5-HT3 CINV market Product portfolio expansion Pending acquisition of Guilford Pharmaceuticals Aquavan® injection pivotal program to begin (proce
Slide 4: Guilford Pharmaceuticals: Strategic Rationale
MGI PHARMA Guilford Pharmaceuticals: Strategic Rationale Complementary Franchises in Oncology & Acute Care Aquavan® Injection Complements Aloxi® injection for PONV >$250 million U.S. revenue potential Pivotal program planning underway Gliadel® Wafer Fits current oncology focus 2004 sales totaled $27
Slide 5: A Leading Biopharmaceutical Company
MGI PHARMA A Leading Biopharmaceutical Company Marketed products Clinical development pipeline Dacogen™ injection (MDS, AML) Saforis™ oral suspension (oral mucositis) Aloxi® injection (PONV) & Aloxi® oral formulation Aquavan® injection (procedural sedation) ZYC101a (cervical dysplasia) Irofulven (HR
Slide 6: Aloxi: The Best in Class 5-HT3 Antagonist for CINV
The Best in Class 5-HT3 Antagonist for CINV Approved for both acute and delayed chemotherapy-induced nausea & vomiting (CINV) Favorable head-to-head trials vs. competitive agents 1H05 sales of $118 million #1 share position in IV CINV market Franchise expansion includes post-operative nausea & vomit
Slide 7: Post Operative Nausea & Vomiting (PONV)
Post Operative Nausea & Vomiting (PONV) PONV is common with anesthesia and surgical procedures Prevalent in gynecological, abdominal, and ear, nose and throat surgeries Incidence of PONV estimated at 25% to 30% ~ 30 million doses of 5-HT3 RAs used annually in U.S. for PONV Can delay hospital dischar
Slide 8: A Leading Biopharmaceutical Company
MGI PHARMA A Leading Biopharmaceutical Company Marketed products Clinical development pipeline Dacogen™ injection (MDS, AML) Saforis™ oral suspension (oral mucositis) Aloxi® injection (PONV) & Aloxi® oral formulation Aquavan® injection (procedural sedation) ZYC101a (cervical dysplasia) Irofulven (HR
Slide 9: Dacogen: Anti-Cancer Agent with Broad Clinical Activity
Anti-Cancer Agent with Broad Clinical Activity Myelodysplastic syndromes (MDS) MAA accepted for review by EMEA Approvable Letter received from FDA Alternative dosing regimen studies ongoing Phase 2 acute myeloid leukemia (AML) trial in elderly patients underway Expanded AML clinical program planned
Slide 10: Saforis: Supportive Care Agent for Oral Mucositis
Supportive Care Agent for Oral Mucositis Proprietary oral formulation (Up-Tec™) of L-glutamine Pivotal phase 3 trial complete in breast cancer patients Primary endpoint met (p=0.026): overall 22% risk reduction (WHO³2) vs. placebo Significant activity in prevention of WHO grade 3 mucositis NDA submi
Slide 11: ZYC101a: Immunotherapeutic for Cervical Dysplasia
ZYC101a Immunotherapeutic for Cervical Dysplasia Immune response therapeutic for treatment of cervical dysplasia, a precancerous condition Phase 2 study completed in 161 patients: In a prospectively defined population of patients under age 25, resolution of high grade dysplasia observed in 70% vs. 2
Slide 12: Irofulven: A Novel, Broadly Active Cytotoxic
A Novel, Broadly Active Cytotoxic New chemotherapeutic class with a novel mechanism of action Monotherapy activity in prostate, liver, ovarian and pancreatic cancers Combination activity in prostate, colorectal and thyroid cancers Strong patent position and exclusive worldwide rights Multi-arm, rand
Slide 13: 2005 Financial Guidance
2005 Financial Guidance Provided July 21, 2005 Excluding any impact of the GLFD transaction: Total revenues of $285 million Aloxi sales of $260 million Other product sales, promotion and licensing revenue of $25 million COGS of $97 million SG&A of $80 million Net R&D of $46 million Operating income
Slide 14: Balance Sheet (In Thousands)
Balance Sheet (In Thousands) June 30, 2005 ACTUAL Cash and Unrestricted Marketable Investments1 $218,845 Total Assets $439,519 Long-term Debt $260,172 Total Shareholders’ Equity $138,090 Shares Outstanding2 75,703 1. Excludes equity investments 2. Excludes approx. 8.3 million common shares issuable
Slide 15: Goals for 2005
Goals for 2005 Revenue: Achieve U.S. sales of Aloxi injection of $260 million Achieve other product sales, promotion and licensing revenue of $25 million Product candidates: Complete pre-launch activities for Dacogen injection for MDS and obtain regulatory approvals Provide analyses requested in App
Slide 16: Building a Leading Oncology and Acute Care Focused Biopharmaceutical Company
Building a Leading Oncology and Acute Care Focused Biopharmaceutical Company BioCentury NewsMakers September 9, 2005